Skip to content

Postoperative Recovery Outcomes in Women Undergoing Hysterectomy Receiving Probiotics: A Randomized Controlled Trial

Postoperative Recovery Outcomes in Women Undergoing Hysterectomy Receiving Probiotics: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251128004
Enrollment
94
Registered
2025-11-28
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative gastrointestinal dysfunction associated with abdominal hysterectomy particularly postoperative ileus, delayed bowel motility, abdominal distension, nausea/vomiting, and postoperative infections which may be influenced by inflammatory process. The study evaluates whether perioperative probiotic supplementation using Saccharomyces boulardii can improve bowel recovery and reduce postoperative complications. Probiotics, Saccharomyces boulardii, Hysterectomy, Postoperative recovery out

Interventions

Bioflor 1 tab orally twice a day for 7 day before surgery,Standard treatment for preoperative, perioperative and postoperative
Experimental Dietary Supplement,No Intervention No treatment
Bioflor before surgery,Control

Sponsors

Rajavithi Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Participants diagnosed with benign gynecologic conditions requiring abdominal hysterectomy (open surgery) at Rajavithi Hospital, scheduled as elective procedures. 2.Participants aged 30-60 years. 3.Participants who are able to communicate Thai proficiently. 4.Participants who have a functional mobile phone for communication. 5.Participants who are willing to voluntarily participate in the study.

Exclusion criteria

Exclusion criteria: 1.Participants who have undergone more than one previous abdominal surgery. 2.Participants with immunocompromised conditions, such as HIV infection, poorly controlled diabetes mellitus (HbA1C > 8%), or autoimmune diseases requiring immunosuppressive therapy. 3.Participants with gastrointestinal disorders, including irritable bowel syndrome, chronic constipation, or chronic diarrhea. 4.Participants with known allergy to probiotics or any components of probiotic yeast formulations. 5.Participants with lactose intolerance. 6.Participants who consume less than 80% of the assigned probiotic doses (assessed through daily intake logs and pill counts upon hospital admission). 7.Participants who are pregnant or breastfeeding. 8.Participants who refuse to undergo the scheduled surgery.

Design outcomes

Primary

MeasureTime frame
time to normoactive bowel sounds during postoperative Hours, assessed by auscultation

Secondary

MeasureTime frame
time to first flatus, first defecation, first ambulation post operative Patient reported,length of hospital stay At hospital discharge Hour,surgical site infection 7 days, 2 weeks and 1 month, and 30-day Physical examination,Readmission rate 30-day Medical record

Countries

Thailand

Contacts

Public ContactPinsuda Suwannarit

Rajavithi hospital

yokpinsuda121139@gmail.com0873425182

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026